Neil Dalal

Bortezomib (Velcade), rituximab, cyclophosphamide, and dexamethasone combination regimen is active as front-line therapy of low-grade non-Hodgkin lymphoma.

C. Nabhan, D. Villines, A. Starr, 2012, Clinical lymphoma, myeloma & leukemia.

Biologic agent activity in chronic lymphocytic leukemia: a framework for future therapies

J. Mehta, C. Nabhan, N. Kay, 2011, Leukemia & lymphoma.

Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis.

Scott E. Smith, J. Vose, A. Zelenetz, 2014, Blood.

in double-hit lymphoma: a multicenter retrospective analysis Impact of induction regimen and stem cell transplantation on outcomes

Scott E. Smith, J. Vose, A. Zelenetz, 2014 .

Impact Of Induction Regimen and Consolidative Stem Cell Transplantation In Patients With Double Hit Lymphoma (DHL): A Large Multicenter Retrospective Analysis

Scott E. Smith, J. Vose, A. Zelenetz, 2013 .

Copper deficiency mimicking myelodysplastic syndrome

T. Lestingi, R. Sirota, R. Mariani, 2015, Clinical case reports.